

10TH ANNUAL

# Shaping the Management of Parkinson's Disease

A special weekend CME program with Parkinson Study Group investigators  
in joint providership with Cleveland Clinic

**June 8-9, 2024**

**Hyatt Regency Coconut Point  
Bonita Springs, Florida**



## OVERVIEW

Innovations and advances in the field of PD—including evaluation, treatment, and prevention—continue to occur at a rapid pace, challenging both specialists and generalists to stay abreast of the changes, creating gaps in knowledge, competence, and practice among health care providers. In many cases, the data are not clear regarding the clinical implications. In turn, this creates a pressing educational activity focused on providing updates and critical analyses of both the pros and cons of the most recent advances in the care of patients with PD.

## LEARNING OBJECTIVES

After completing this educational activity, participants will be able to do the following:

- Discuss the role of alpha-synuclein in the initiation of nigrostriatal dopaminergic neurodegeneration, and whether its presence is a defining feature of PD.
- Describe the sensitivity and specificity of skin biopsies in detecting alpha synuclein pathology and the challenges to their use in the diagnosis of early PD.
- Summarize the treatment outcomes of deep brain stimulation and other device-aided therapies in patients with various genetic profiles of monogenic parkinsonism.
- Detail the progress made in the use of various stem-cell based treatments as a useful regenerative therapy for PD, and the promise that they hold in the future.
- Describe the shortcomings of epidemiology and clinical research design and discuss possible study designs that can be used for evaluating new approaches to disease-modifying therapies for PD.
- Critically assess the potential benefits of cannabis in treating PD-related tremor, anxiety, pain, and improvement of sleep quality and quality of life, as well as the quality of evidence to support each.
- Recognize key clinical and pathologic features of various atypical parkinsonian disorders, including those based on tissue and imaging biomarkers that may permit earlier and more selective treatment options for each.
- List and assess the investigational agents that hold the most promise to reduce symptom burden in PD and the research describing their efficacy.
- Discuss optimal use of infusion therapies in advanced PD management.
- Summarize the progress made in imaging techniques, hardware, lead design, and software that have enabled newer programming strategies to improve the efficacy of deep brain stimulation for PD while minimizing stimulation-induced side effects.
- Evaluate the evidence to support behavioral and cognitive therapies to treat common psychiatric symptoms in PD.

## TARGET AUDIENCE

This educational activity is intended for neurologists, neurosurgeons, nurse practitioners, nurses, residents, fellows, and other health care professionals who treat patients with Parkinson's Disease.

## CO-DIRECTORS



**Hubert H. Fernandez, MD**  
Co-Chair, PSG Executive Committee  
James and Connie Brown Endowed Chair in Movement Disorders  
Professor of Neurology, Cleveland Clinic Lerner College of Medicine of CWRU  
Director, Center for Neurological Restoration, Cleveland Clinic, Cleveland, Ohio



**Michael Schwarzschild, MD, PhD**  
Chair, PSG Executive Committee  
Julianne Dorn Professor of Neurology  
Harvard Medical School  
Boston, Massachusetts

## FACULTY



**Alberto Espay, MD**  
University of Cincinnati  
Cincinnati, Ohio



**Irene Malaty, MD**  
University of Florida Health  
Gainesville, Florida



**Kathleen Poston, MD, MS**  
Stanford University  
Stanford, California



**Eric Farbman, MD**  
Community Neurosciences Institute  
Fresno, California



**Tiago Mestre, MSc, MD**  
University of Ottawa  
Ottawa, Ontario, Canada



**Adolfo Ramirez-Zamora, MD**  
University of Florida Health  
Gainesville, Florida



**Alfonso Fasano, MD, PhD, FAAN**  
Toronto Western Hospital  
Toronto, Ontario, Canada



**Martha Nance, MD**  
Struthers Parkinson's Center  
Golden Valley, Minnesota



**Liana Rosenthal, MD, PhD**  
Johns Hopkins School of Medicine  
Baltimore, Maryland



**Claire Henchcliffe, MD, DPhil**  
University of California, Irvine  
Orange, California



**William Ondo, MD**  
Houston Methodist Neurological  
Institute | Houston, Texas



**Diego Torres-Russotto, MD, FAAN**  
Baptist Health Medical Group  
Miami, Florida



**Drew Kern, MD, MS**  
University of Colorado  
Aurora, Colorado



**Alexander Pantelyat, MD, FAAN**  
Johns Hopkins School of Medicine  
Baltimore, Maryland



**Thomas Tropea, DO**  
University of Pennsylvania  
Philadelphia, Pennsylvania



**Corneliu Luca MD, PhD**  
University of Miami,  
Miller School of Medicine  
Miami, Florida



**Greg Pontone, MD, MHS**  
University of Florida,  
College of Medicine  
Gainesville, Florida

## ADDITIONAL PLANNER/REVIEWER

**Cynthia Willis, DNP, MSN, RN, MBA, CMSRN**  
Cleveland Clinic  
Cleveland, Ohio




## SATURDAY, JUNE 8, 2024: CONTROVERSIES

7:30 AM	<b>Registration/Continental Breakfast/Exhibits</b>
8:25 AM	<b>Welcome and Introductions</b> Hubert Fernandez
Moderator:	Diego Torres-Russotto
8:30 AM	<b>Hope vs. Hype I:</b> It is time to redefine and rename Parkinson disease based on alpha synuclein Agree: Kathleen Poston Disagree: Tiago Mestre
9:30 AM	<b>Convention vs. Innovation I:</b> Skin biopsy for synuclein inclusions should now be used in the clinical setting Agree: Drew Kern Disagree: Liana Rosenthal
10:30 AM	<b>Refreshment Break/Exhibits</b>
11:00 AM	<b>Convention vs. Innovation II:</b> Genetic profiles should be a standard consideration in the assessment for DBS candidacy Agree: Thomas Tropea Disagree: Adolfo Ramirez-Zamora
12:00 PM	<b>Lunch/Exhibits</b>
Moderator:	Irene Malaty
1:00 PM	<b>Convention vs. Innovation III:</b> The promise of stem cell therapy in Parkinson disease remains bright and getting brighter Agree: Claire Henchcliffe Disagree: Alfonso Fasano
2:00 PM	<b>Hope vs. Hype II:</b> We should stop embarking on epidemiology-based disease-modifying clinical trials Agree: Alberto Espay Disagree: Michael Schwarzschild
3:00 PM	<b>Refreshment Break/Exhibits</b>
3:30 PM	<b>Hope vs. Hype III:</b> We should be more open to endorsing cannabis for Parkinson disease Agree: Eric Farbman Disagree: Diego Torres-Russotto
4:30 PM	<b>Preview on the Updates Session: The State of Genetics in PD</b> Martha Nance
5:15 PM	<b>Adjourn</b>
5:15–6:30 PM	<b>Welcome and Networking Reception</b>

## SUNDAY, JUNE 9, 2024: UPDATES

7:30 AM	<b>Refreshment Break/Exhibits</b>
Moderator:	Irene Malaty
8:00 AM	<b>Advances in Atypical Parkinsonian Disorders</b> Alexander Pantelyat
8:45 AM	<b>The Most Promising Symptomatic Therapies in PD</b> William Ondo
9:30 AM	<b>Brunch/Exhibits</b>
10:15 AM	<b>Current and Emerging Infusion Therapies in PD</b> Hubert Fernandez
11:00 AM	<b>Advances in Deep Brain Stimulation Surgery</b> Corneliu Luca
11:45 AM	<b>Progress in Behavioral and Cognitive Therapies in PD</b> Gregory Pontone
12:30 PM	<b>Adjourn</b>





## LOCATION

Discover family-friendly luxury at Hyatt Regency Coconut Point Resort, perfectly situated at the heart of Southwest Florida. With only a 20-minute drive to Naples, Fort Myers, and the RSW International Airport, your dream getaway is closer than you think.

### Hyatt Regency Coconut Point Resort and Spa

5001 Coconut Road  
Bonita Springs, FL 34134  
239.444.1234

## HOTEL ACCOMMODATIONS

A limited block of rooms has been reserved at the Hyatt Regency Coconut Point until **Friday, May 17, 2024**. To make your reservations, please [click here](#) or call the 877.803.7534 and identify yourself as being with the **Cleveland Clinic Foundation—Parkinson Study Group** meeting for a special rate of \$239 (plus resort fee and applicable taxes). After this date, the discounted group rate may not be available.

## PARKING

Hyatt Regency Coconut Point has valet and self-parking available to their guests at prevailing rates.





# ACCREDITATION

In support of improving patient care, this activity has been planned and implemented by Cleveland Clinic Center for Continuing Education and Parkinson Study Group. Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## American Medical Association (AMA)

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

## American Board of Surgery (ABS)

Successful completion of this CME activity enables the learner to earn credit toward the CME requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Credit will be reported within 30 days of claiming credit.

## American Nurses Credentialing Center (ANCC)

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 10.50 ANCC contact hours.

## Certificate of Participation

A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.

# INFORMATION

For further information about this activity, contact Liz Eaton.  
Phone: 216.445.5431  
Email: [eatonl3@ccf.org](mailto:eatonl3@ccf.org)

# FACULTY DISCLOSURE

The Cleveland Clinic Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Integrity and Independence requiring mitigation of all faculty conflicts of interest. Faculty declaring a relevant financial relationship will be identified in the activity syllabus.

# HEALTH AND SAFETY

As participants are responsible for their own health choices, the use of masks by all participants at this event is optional. Additionally, attendees are not required to verify vaccination status nor to provide a negative COVID-19 test for entry. Please note this is subject to change based on the most recent status of CDC, local and/or state guidelines.

# AMERICANS WITH DISABILITIES ACT

The Cleveland Clinic Center for Continuing Education fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify us at least two weeks prior to the activity.

# REGISTRATION & CANCELLATION

Register online at [www.ccfme.org/shapingPD](http://www.ccfme.org/shapingPD)

Preregistrations are accepted online until 9:00 AM ET June 5, 2024. To register after this date, please do so onsite. In case of cancellation, a full refund will be made if canceled by May 20, 2024. After May 20, 2024, a 50% cancellation fee will be deducted from your refund. Written notification of your cancellation is required to process your refund. **No refunds will be issued after June 8, 2024.** For questions about registering online, call 216.448.8710 or email [cmeregistration@ccf.org](mailto:cmeregistration@ccf.org)

Fee includes syllabus, continental breakfasts, refreshment breaks, and Saturday lunch and reception.		
	PSG Member**	Non-PSG Member
Physician	\$0	\$200
Industry Representative	\$0	\$200
Non-Physician	\$0	\$100
Resident/Fellow*	\$0	\$75
*Letter from program director must be received in our office prior to the course to receive this fee. **All PSG memberships will be verified before the meeting.		

Cleveland Clinic reserves the right to cancel or postpone an activity at our sole discretion. In the unlikely event that this occurs, any registration fee(s) paid will be refunded. Be advised that Cleveland Clinic is not responsible for related costs including airline tickets, hotel costs, or any similar fee penalties incurred as a result of any trip cancellations or changes.